Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario Reina Sofia (22)

2024

  1. Criteria and indicators to evaluate quality of care in genitourinary tumour boards

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1639-1646

  2. Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

    Clinical and Translational Oncology, Vol. 26, Núm. 6, pp. 1532-1538

  3. Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer

    Cancers, Vol. 16, Núm. 14

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

2022

  1. Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain

    Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 495-502

2020

  1. Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer

    European Urology

  2. Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE

    Therapeutic Advances in Medical Oncology, Vol. 12

  3. Latest progress in molecular biology and treatment in genitourinary tumours

    Clinical and Translational Oncology, Vol. 22, Núm. 12, pp. 2175-2195

2019

  1. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

    European Urology, Vol. 75, Núm. 3, pp. 368-373

  2. Prorepair-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer

    Journal of Clinical Oncology, Vol. 37, Núm. 6, pp. 490-503

2018

  1. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286

2017

  1. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study

    Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9

  2. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

    Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421

  3. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment

    Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190

2016

  1. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations

    Targeted Oncology, Vol. 11, Núm. 2, pp. 129-141

  2. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

    BMC Cancer, Vol. 16, Núm. 1

2015

  1. New advances in genitourinary cancer: evidence gathered in 2014

    Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 443-464

2014

  1. Erratum to: Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer (Targeted Oncology (2014) 9, (9-24) DOI: 10.1007/s11523-013-0304-7)

    Targeted Oncology

  2. Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer

    Targeted Oncology, Vol. 9, Núm. 1, pp. 9-24

  3. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma

    Cancer Chemotherapy and Pharmacology, Vol. 73, Núm. 6, pp. 1095-1107